Advanced Stage Hodgkin’s Lymphoma

CAR Therapy Effective in Advanced Lymphoma (06-20-2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

Keytruda PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma (12-23-2014)

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researchers at the American Society of Hematology (ASH) 56th... Continue Reading

PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma (12-18-2014)

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researcher recently published in The New England Journal of... Continue Reading

Post-Transplant Adcetris® Improves Treatment of Hodgkin’s Lymphoma and is Likely to Become New Standard of Care (12-12-2014)

The use of post stem cell transplant (SCT) maintenance therapy with Adcetris® (brentuximab vedotin) significantly improved progression-free survival in Hodgkin’s Lymphoma (HL) according to the results of a clinical trail presented at the 56th American... Continue Reading

Rituxan Active in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma (02-26-2014)

Rituxan® (rituximab) was active in previously treated and untreated patients with nodular lymphocyte–predominant Hodgkin lymphoma, according to the results of a phase II study published in the Journal of Clinical Oncology. Most patients relapsed,... Continue Reading

Adcetris and PET-Adapted Salvage Therapy Effective in Relapsed/Refractory Hodgkin’s Lymphoma (01-16-2014)

Patients with relapsed/refractory Hodgkin’s lymphoma who achieve complete responses after treatment with Adcetris® (brentuximab vedotin) can skip more toxic salvage therapy and proceed straight to transplant, according to the results of a study presented... Continue Reading

Adcetris Improves Response Rates to ABVD in Hodgkin’s Lymphoma (01-2-2013)

Adding Adcetris® (brentuximab vedotin) to the chemotherapy regimen ABVD produces a high complete response rate with a moderate increase in toxicity in patients with advanced Hodgkin’s lymphoma, according to the results of a study presented at the 19th... Continue Reading

Lymphoma During Pregnancy Can Have Good Outcomes (03-14-2012)

Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester of pregnancy, as well as women who deferred treatment... Continue Reading

Similar Overall Survival with ABVD and BEACOPP for Advanced Hodgkin’s Lymphoma (07-25-2011)

Although the BEACOPP chemotherapy regimen produces better initial tumor control than the commonly used and less toxic ABVD regimen, the two regimens produce similar overall survival among patients with advanced Hodgkin’s lymphoma. These results were... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (05-23-2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

Next Page »